Successful treatment of critical coronavirus disease 2019 in a patient with lung cancer concomitant with pembrolizumab-induced arthritis by methylprednisolone, baricitinib, and remdesivir.

Oda, Naohiro; Miyoshi, Keiji; Morichika, Daisuke; Beika, Yuka; Taki, Takahiro; Mitani, Reo; Okada, Toshiaki; Takata, Ichiro

Oda, Naohiro; Miyoshi, Keiji; Morichika, Daisuke; Beika, Yuka; Taki, Takahiro; Mitani, Reo; Okada, Toshiaki; Takata, Ichiro.

Oda N; Department of Internal Medicine Fukuyama City Hospital Fukuyama Japan.
Miyoshi K; Department of Respiratory Medicine Fukuyama Medical Center Fukuyama Japan.
Morichika D; Department of Respiratory Medicine Fukuyama Medical Center Fukuyama Japan.
Beika Y; Department of Respiratory Medicine Fukuyama Medical Center Fukuyama Japan.
Taki T; Department of Internal Medicine Fukuyama City Hospital Fukuyama Japan.
Mitani R; Department of Internal Medicine Fukuyama City Hospital Fukuyama Japan.
Okada T; Department of Respiratory Medicine Fukuyama Medical Center Fukuyama Japan.
Takata I; Department of Internal Medicine Fukuyama City Hospital Fukuyama Japan.

Clin Case Rep ; 9(7): e04459, 2021 Jul.

Article in English | MEDLINE | ID: covidwho-1300375

ABSTRACT

ABSTRACT

COVID-19 in cancer patients on immunosuppressive agents for the treatment of immune-related adverse events of immune checkpoint inhibitors can rapidly deteriorate. The combination therapy with methylprednisolone, baricitinib, and remdesivir may be effective for critical COVID-19, and further clinical trials are warranted.

Keywords

COVID19; baricitinib; immune checkpoint inhibitor; immunerelated adverse event; lung cancer

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Case report / Prognostic study Language: English Journal: Clin Case Rep Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google